POPULARITY
49 episodes with clinical studies
9 episodes with clinical studies
5 episodes with clinical studies
2 episodes with clinical studies
10 episodes with clinical studies
2 episodes with clinical studies
2 episodes with clinical studies
2 episodes with clinical studies
2 episodes with clinical studies
Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/
Episode 299 hosts Dr Darryl Reed (Biochemist & COO of Tissue Repair from Sydney, Australia) and Charlotte Meli (Registered Nurse and NSW Territory Manager of Tissue Repair from Sydney, Australia) In this episode we learn about Tissue Repair and their unique product TR Pro +. This novel hydrogel product contains beta-glucans (a derivative from yeast) and has been clincically proven and is TGA-approved to help wound healing. We find out who Tissue Repair are, the science behind TR Pro + and how this can be applied in aesthetic practices. This podcast was supported by Tissue Repair 00:30 Introduction 00:42 Our Upcoming 300th Podcast and IA Competition 02:01 Introducing Tissue Repair and TR Pro + 02:23 Darryl Reed's Journey into Aesthetics 04:10 Charlotte Meli's Background and Role 05:18 The Origins and Development of TR Pro + 07:41 Understanding Beta Glucans and Their Benefits 16:19 TGA Approval and Market Expansion 18:01 Clinical Studies and Real-World Evidence 22:18 Versatility and Benefits of TR Pro + 22:50 Clinical Feedback and Usage 23:35 Post-Injectable Applications 24:33 Science Behind the Semi-Permeable Film 25:15 Contraindications and Safety 27:38 Anti-Itching and Inflammation Control 29:04 Scar Treatment and Healing 30:17 Product Availability and Pricing 37:13 Future Developments and Applications 41:13 Conclusions and Final Thoughts READ THIS GUIDE TO JOIN OUR PATREON AS A FREE MEMBER OR SUBSCRIBE TO OUR PATREON FOR EXCLUSIVE PODCASTS, WEEKLY EDUCATIONAL CONTENT & JOIN OUR WHATSAPP COMMUNITY CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST CONTACT US
Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/
In EPISODE 205 OF GROWING OLDER LIVING YOUNGER,host,Dr. Gillian Lockitch, welcomes Eugene Zabolotsky, founder and CEO of Health Helper, a pioneer in nature-inspired consumer medical devices. With over two decades in the pharmaceutical and medical tech industries, Eugene has made it his mission to create affordable, accessible solutions for common health issues—from bug bites to menstrual pain to muscle recovery. He developed the Bite Helper, a hand-held device using thermal pulse technology to alleviate the itch and sting of insect bites. Launched in 2017, the Bite Helper is available in the US and globally, and is particularly effective in regions with year-round mosquito issues. Eugene also discusses the Muscle Helper, a TENS device for muscle rehabilitation, and his future plans for developing military-grade, rugged versions of his products. In the conversation he emphasizes the potential of medical devices to transform consumer health. In this episode, Eugene shares his entrepreneurial journey from working with Big Pharma to creating startup innovations. He explains how the Bite Helper uses heat to stop itching and potentially disrupt mosquito-borne disease transmission. They also discuss the future of at-home health tech, including mobile-powered devices and wearable stress management tools. Episode Timeline: Episode Timeline: 0:00 – Introduction and Overview Kick off the episode with a warm welcome and a preview of what's to come. 4:05 – Eugene Zabolotsky's Background and Career Journey Learn about Eugene's path from entrepreneur to innovator in health tech. 8:50 – Innovation and Development of the Bite Helper Discover how the Bite Helper was created and how it works to relieve itch and irritation. 12:47 – Clinical Studies and Market Expansion We explore the science behind the product and how it's scaling to new global markets. 19:13 – Consumer Market and Product Availability Where can you find it? Insights into retail growth and customer adoption. 22:13 – Muscle Helper and Other Products Eugene shares new product developments and what's next from his team. 33:27 – Military Applications and Future Innovations Unexpected uses for these wellness tools and how they're being adopted in new fields. 33:51 – Conclusion and Key Takeaways Final thoughts on innovation, wellness, and empowering consumer health solutions. Action Steps: Check out Gillian's blog “ Age is Just a Number” in the A to Z 2025 Blogging Challenge Schedule a FREE CALL with Dr. Gillian Lockitch. Join the GOLY Community: https://www.facebook.com/groups/growingolderlivingyounger Learn about Eugene Zabolotsky and Health Helper at the links below. https://eugene.health/ https://www.instagram.com/eugene.zabolotsky/ https://www.linkedin.com/in/eugene-zabolotsky/
If your hair is thinning, shedding, or simply not what it used to be—and nothing seems to work—this episode is for you. Because what if the story you've been told about balding… is wrong? For decades, hair loss has felt like fate: genetic, inevitable, untouchable. But science is catching up to something deeper—something root-level. What if the real culprit behind age-related hair loss is cellular dysfunction? And what if we could change that? In this episode, Dave Asprey uncovers the cellular biology of hair thinning with longevity researcher Carolina Reis Oliveira. You'll learn how senescent cells (aka zombie cells) hijack your scalp, disrupt follicle function, and silently accelerate hair loss—and how a breakthrough peptide might stop it cold. Carolina reveals brand-new clinical research on OS-01, a molecule shown to increase hair density by 40% in just 6 months. But this isn't a product pitch—it's a paradigm shift. Together, they explore the hidden drivers of hair aging, from hormone shifts and stress cascades to microbiome imbalances and inflammation, plus the real science behind what can actually regrow hair. What You'll Learn in This Episode: • How “zombie cells” (senescent cells) sabotage your hair from the inside out • The science behind the OS-01 peptide and how it reverses visible hair thinning • Why thinning hair isn't just genetic—and what else is driving it • How stress, hormones, and aging collide to trigger follicle dysfunction • What your scalp microbiome has to do with regrowth and hair density • How to stack red light, peptides, and topicals for real, measurable results ***Visit oneskin.co/DAVE and use code DAVE for and additional 15% off.*** Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • OneSkin Instagram – https://www.instagram.com/oneskin.co/ • OneSkin Website: https://www.oneskin.co/ • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 — Trailer • 01:52 — Intro • 02:59 — Is Aging Optional for Your Scalp? • 04:03 — Understanding Scalp and Hair Aging • 05:06 — The Role of Senescent Cells in Hair Loss • 07:25 — Hormonal Influences on Hair Health • 16:10 — Peptide Solutions for Hair Thinning • 18:05 — Clinical Studies and Results • 20:29 — Future of Hair Loss Treatments • 30:16 — Nutritional and Lifestyle Factors • 36:40 — Addressing Senescent Cells and Hair Growth • 37:29 — Minoxidil: Oral vs. Topical Use • 39:32 — Personal Experience with Hair Products • 40:25 — Combining Therapies for Hair Growth • 46:06 — Nutritional Factors in Hair Health • 52:20 — Sun Exposure and Hair Health • 56:40 — Coffee and Hair Growth • 01:00:01 — Launching the New Hair Product See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Text Dr. Lenz any feedback or questions In this episode of the Conquering Your Fibromyalgia podcast, Dr. Michael Lenz delves into the complex relationship between hormones and chronic pain conditions such as fibromyalgia, migraines, dysmenorrhea, and others. The focus is on Premenstrual Dysphoric Disorder (PMDD), exploring the impact of estrogen and progesterone fluctuations on pain perception and symptom management. Key studies are discussed to highlight the relationship between menstrual cycles and fibromyalgia symptoms. The episode also covers the genetic, neurobiological, and environmental factors contributing to PMDD, as well as treatment options ranging from SSRIs and hormonal treatments to lifestyle changes and cognitive behavioral therapy. The intricate link between ADHD in women and mood disorders like PMDD and depression is also examined.00:00 Introduction to Hormones and Chronic Pain00:56 Understanding Hormonal Fluctuations02:26 Clinical Studies on Hormones and Pain03:48 The Role of Estrogen and Progesterone04:42 Historical Perspective on Premenstrual Disorders06:28 Diagnosing PMDD: Symptoms and Criteria07:39 Causes and Brain Sensitivity in PMDD09:35 Genetic and Neurobiological Factors10:45 Serotonin and Allopregnanolone in PMDD12:06 Stress, Inflammation, and PMDD13:33 Treatment Options: SSRIs and Hormonal Therapies16:26 Advanced Treatments and Surgical Options21:06 ADHD and Hormone-Related Mood Disorders27:43 Managing PMDD: Lifestyle and Non-Pharmacological Approaches31:12 Conclusion and Final Thoughts Click here for the Fibromyalgia 101 link.Click here to connect with Joy Lenz. Support the showA Fibromyalgia Starter Pack, a great companion to the book Conquering Your Fibromyalgia, is now available. Dr. Michael Lenz practices general pediatrics and internal medicine primary care, seeing patients from infants through adults. In addition, he also will see patients with fibromyalgia and related problems and patients interested in lifestyle medicine and clinical lipidology. To learn more, go to ConquringYourFibromyalgia.com. Remember that while Dr. Lenz is a medical doctor, he is not your doctor. All of your signs and symptoms should be discussed with your physician. He aims to weave the best of conventional medicine with lifestyle medicine to help people with chronic health conditions live their best lives possible. Dr. Lenz hopes that the podcast, book, blog, and website serve as a trusted resource and starting point on your journey of learning to live better with fibromyalgia and related illnesses. Junior Producer- Brooklyn Lenz
For this episode, we discuss the roles and sensitivity of mitochondria with Dr. Richard Frye, MD, PhD. Dr. Frye received an MD and a PhD in Physiology and Biophysics from Georgetown University. He is board certified in Pediatrics, Neurology with special competence in Child Neurology, and as a Certified Principal Investigator. In addition, he has a Masters in Biomedical Sciences and Biostatistics from Drexel University. Dr. Frye has over 300 publications in leading journals and book chapters.Dr. Frye shares many figures during the conversation so the listener can follow along.Dr. Richard Frye https://drfryemdphd.comRossingnol Medical Center Facebook https://www.facebook.com/RossignolMedicalCenterNeurological Health Foundation https://neurologicalhealth.orgHealthy Child Guide https://neurologicalhealth.org/the-guide-5/Daylight Computer Company https://daylightcomputer.com?sca_ref=8231379.3e0N25Wg3wuse "autism" in the discount code for $25 coupon.This is the future of tech.Chroma Light Therapy https://getchroma.co/?ref=autismuse "autism" for a 10% discount,0:00 Dr. Richard Frye0:58 Daylight Computer Company5:17 Chroma Light Devices8:27 History of Leucovorin; low risk, high reward; Folate Receptor Alpha (FRa)10:25 Blood Brain Barrier; Folate; CSF (cerebral spinal fluid)14:04 DNA, RNA; MTHFR (Methylenetetrahydrofolate reductase)17:34 Cerebral Folate deficiency; BH4, Placenta & Womb23:35 Folate deficiency & Autism26:21 Clinical Studies & Data29:28 Folate & Mitochondria; Cerebral Folate Antibodies; White Matter Findings (!)34:45 Cerebral Folate deficiency & Ranges; Autistic Phenotypes: Language, Communication, & Behaviors40:45 Language & Communication; Self-Injurious Behaviors; Hyperactivity, Agitation; Treatment duration42:53 Folate Autoantibodies & Maternal Health & Markers45:30 Studies & Behavioral outcomes; inflammation & thyroid findings46:58 Neural development; Language connections, white matter tracts & distal connections48:53 Leucovorin for different severity/levels of Autism; Spinal Bifida51:08 Preparing for pregnancy53:50 Transgenerational aspects of Folate Autoantibodies Research; Prenatal Care & Awareness59:32 Guidance & SupportX: https://x.com/rps47586Hopp: https://www.hopp.bio/fromthespectrumYT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com
View the Show Notes For This Episode Dr. Alessandra Zonari discusses How to Reverse Skin Aging with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.] Podcast Highlights Unlocking the Secrets of Skin Longevity with Dr. Alessandra Zonari In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Alessandra Zonari, co-founder and Chief Science Officer of OneSkin. They delve into the science behind skincare and aging, focusing on the revolutionary peptide OS01. Dr. Zonari explains her academic background and the journey of founding OneSkin, the mechanisms by which OS01 reduces skin aging, and the importance of holistic health practices like hydration, sleep, diet, and exercise. They also touch upon the efficacy of topical peptides, the role of free radicals and antioxidants, and the impacts of environmental stressors on skin health. The episode concludes with practical tips for improving skin health and information on OneSkin's product offerings. 00:00 Introduction to Rational Wellness Podcast 00:26 Meet Dr. Alessandra Zonari: Skincare Expert 02:14 Journey to Founding OneSkin 04:54 Understanding Peptides and OSO1 06:33 Mechanisms of Skin Aging and Peptide Benefits 14:14 Clinical Studies and Efficacy of OSO1 22:00 Holistic Approach to Skin Health 31:58 OneSkin Products and Offerings 36:35 Conclusion and Contact Information ___________________________________________________________________________ Dr. Alessandra Zonari is the Co-Founder and Chief Scientific Officer of OneSkin, a disruptive and fast-growing skin longevity company developing products to address the root causes of aging so that skin functions, feels, and appears younger. Dr. Alessandra led the team that identified the OS-01, the world's first cosmetic peptide that reverses aging at the molecular level, showed significant improvement in skin health and appearance in 100% of users, that is being used in the OneSkin products. Try OneSkin for yourself by visiting oneskin.co/RATIONAL and use code RATIONAL for 15% off your first order. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure. Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.
Get My Book On Amazon: https://a.co/d/avbaV48Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/
Register free at https://brightu.com to watch the full Cancer Decoded stream - Brighton Broadcast News Introduction and Feature Interview Announcement (0:00) - Introduction to the Film "Unpacking the Lies" (1:02) - Mike Adams' Music and Bright Learn Video on Health and Light (2:2- 1) - The Importance of Light for Healing and Personal Experience with - Light Therapy (3:25) - Elon Musk's Announcement of Grok 3.0 and AI Industry Critique (7:33) - Elon Musk's Doge Dividend Proposal and Economic Stimulation Ideas (13:28) - Special Report on Enoch AI Model and Domain Adaptation Explanation (18:15) - Brighton AI Model's Capabilities and Future Plans (24:23) - Top Priorities for RFK Jr as Head of HHS (30:32) - Further Suggestions for RFK Jr and the Need for Realism (42:27) - Special Report on Financial Fraud and the Role of Gold (46:17) - Bright Learn Video on "Health and Light" by John Nash Otto (1:14:10) - Light Pollution and Health Issues (1:18:36) - Introduction to Natural News and Sponsors (1:21:32) - Product Promotion and Personal Anecdotes (1:25:30) - Introduction to Jonathan Otto and Cancer Decoded (1:28:55) - Light Therapy and Cancer Treatment (1:31:06) - Clinical Studies and Red Light Therapy (1:35:22) - Challenges in Modern Medicine and Light Therapy (1:45:06) - Bonus Content and Resources in Cancer Decoded (1:49:08) - Light Therapy Devices and Personal Health (1:54:29) - The Role of Light in Healing and Prevention (1:56:26) - Conclusion and Call to Action (2:09:22) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com
Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/
2024-12-06 Hosts Craig Lipset, Amir Kalali, and Jane Myles were joined by Anna Yang and Elizabeth Mandel (Genentech) joined us for a discussion around defining, measuring, and benchmarking data quality with 2 ongoing hybrid studies.You can join TGIF-DTRA Sessions live on LinkedIn Live Audio on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.
On Episode #152 of the PricePlow Podcast, Mike and Ben are joined by Jonathan Scheiman, co-founder and CEO of FitBiomics, to discuss VNella, a revolutionary probiotic strain derived from the microbiomes of elite athletes. The conversation explores how this cutting-edge innovation optimizes endurance, reduces fatigue, and brings next-generation biotechnology to everyday health and performance. VNella: Optimizing Human Performance Through the Microbiome Dive into the science behind VNella, a first-of-its-kind probiotic that metabolizes lactic acid to fuel mitochondria, enhance recovery, and improve overall energy levels. Jonathan shares the groundbreaking journey of FitBiomics, from analyzing the microbiomes of ultra-endurance athletes to developing consumer products that benefit everyone from Olympians to everyday fitness enthusiasts. The trio also explore the role of athletes in product development, the broader applications of microbiome research, and FitBiomics' ambitious vision to transform health and wellness through proprietary probiotics. This is a podcast packed with science, innovation, and practical takeaways for optimizing performance and well-being. Let's dive in! https://blog.priceplow.com/podcast/jonathan-scheiman-fitbiomics-158 Video: Decoding Elite Athletes' Microbiomes and Making VNella at Fitbiomics https://www.youtube.com/watch?v=I2XWUZnpQP8 Detailed Show Notes with Jonathan Scheiman (00:00) – Introduction, Jonathan's Background, and the Origins of Fitbiomics (06:00) – Development of FitBiomics Products (09:30) – The Science of VNella and Lactic Acid Metabolism (11:15) – Explanation of Gut Microbiome's Role in Health and Performance (21:30) – Clinical Studies and Validation of VNella (30:30) – Practical Applications for VNella (45:15) – Athletes and Their Role in Product Development (50:45) – Big Picture and Future of FitBiomics (56:15) – Closing Thoughts and Call to Action Where to Follow Jonathan and Fitbiomics Jonathan Scheiman on LinkedIn @Fitbiomics on Instagram Fitbiomics News on PricePlow Thank you to Jonathan for coming on and educating us! Stay up to date with Fitbiomics' latest news by signing up for PricePlow's alerts below, and don't forget to subscribe to the PricePlow Podcast and leave us a great review!
A scientist-turned-entrepreneur, Bruce Lahn has successfully transitioned from academia to leading businesses like Vector Builder and Cyagen, reshaping gene delivery and genetic research. Here's a dive into his extraordinary path and the lessons he's gleaned along the way. Vector Builder has attracted funding from top-tier investors like Legend Capital, Operation Holding Group, Wanlian Securities Co., Guangzhou Yuexiu Industrial Investment Fund Management, and China Chengtong.
Clinical studies are not always representative of the actual patient population, which can limit our understanding of patient outcomes. Join NPF moderator Takieyah Mathis as we hear from LaShell Robinson and Marygrace Corral with Takeda on why it's so important to ensure diversity in clinical research, what they are doing to improve racial diversity in their clinical studies, and how you can support these efforts. This episode is sponsored by Takeda.
A good gynecologist is like a detective. She gathers evidence to diagnose infections. She uncovers the truth behind stages like puberty, pregnancy and perimenopause. Yet many women still feel that their physiology is a mystery. What if a clue to that mystery hides in our diet? Similar to the gut, certain foods make the vaginal microbiome thrive. New research suggests that the right diet could alleviate symptoms of the most common gynecological diseases. Dr Jennifer Ashton is former Chief Medical Correspondent at ABC News and is a double-board certified OBGYN. She joins us today to discuss ‘nutritional gynecology', a term she coined after realizing multiple women's health issues have a direct relationship to nutrition. Alongside Jen is King's College London professor and ZOE's Chief Scientist Sarah Berry. Sarah shines light on the growing evidence of the role of nutrition in offsetting uncomfortable, and sometimes dangerous, symptoms of menopause.
Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation
Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________
In this episode of The Human Upgrade, Dave Asprey is joined by Dr. Stephanie Venn-Watson, a veterinary epidemiologist and co-founder of Seraphina Therapeutics, to explore the groundbreaking discovery of C15, also known as Pentadecanoic acid. This episode uncovers how Dr. Venn-Watson's work with aging dolphins in the U.S. Navy led to the surprising revelation that C15 is an essential fatty acid, marking the first discovery of its kind in nearly a century. Through extensive research, C15 has shown powerful benefits for longevity, reducing inflammation, and promoting cellular health, which can help prevent chronic conditions like metabolic syndrome and heart disease. Dr. Venn-Watson explains the science behind C15, its natural sources—such as grass-fed dairy and certain types of fish—and why it's often missing from modern low-fat diets. She also dives into the clinical studies that reveal how C15 can stabilize cell membranes, reduce oxidative stress, and improve metabolic function. The episode emphasizes the importance of this ‘new' fat for anyone seeking to optimize their health, whether through diet or supplementation. Sponsors: Fatty15 | Go to https://fatty15.com/dave and save an extra $15 when you subscribe with code DAVE. Resources: Dr. Stephanie Venn-Watson's Company: Seraphina Therapeutics Dr. Stephanie Venn-Watson's Instagram: @fatty15 Learn More About C15: discoverC15.com Dave's Linktree: https://linktr.ee/daveasprey Dave Asprey's Book ‘Smarter Not Harder' is out now: https://daveasprey.com/books Want to join The Human Upgrade Podcast Live? Join Our Upgrade Collective: https://www.ourupgradecollective.com/ Danger Coffee by Dave Asprey: https://www.instagram.com/dangercoffeeofficial/ Supplements by Dave Asprey: https://shopsuppgradelabs.com/ Own an Upgrade Labs: https://ownanupgradelabs.com/ Timestamps and Highlights: 00:00:01 — Introduction by Dave Asprey 00:01:02 — Dr. Stephanie Venn-Watson's Introduction 00:03:15 — The Discovery of C15 00:05:56 — C15 in Fish and Dairy 00:08:03 — C15's Role in Longevity and Cellular Health 00:12:35 — Clinical Studies and Health Benefits 00:20:12 — C15 and Vegan Diets See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Brigitte Brisson, DMV, DVSc, DACVS from the Ontario Veterinary College at the University of Guelph joined us on OsteoBites to introduce Magnetic Resonance guided High Intensity Focused Ultrasound as a treatment modality for osteosarcoma and describe preliminary results in canine patients.High Intensity focused ultrasound (HIFU) is a non-invasive percutaneous thermal ablation technique that allows deep tissue treatment with precise control over the shape and location of energy deposition. It causes minimal collateral damage and can be used to treat primary and metastatic tumours. In addition to its role in tumour ablation, HIFU has attracted attention for its potential to stimulate the immune system and possibly mount a response against metastasis. In humans, HIFU has been used for ablation of a variety of soft tissue tumours and most recently, it has been used in bone applications, specifically for the treatment of osteoid osteoma (OO) lesions in pediatric patients. Other reported bone applications include bone metastasis and osteosarcoma.Dr. Brigitte Brisson is a professor of soft tissue surgery in the Department of Clinical Studies at the Ontario Veterinary College (OVC). She graduated from the Faculté de Médecine Vétérinaire at the University of Montreal in 1996. She performed a small animal rotating internship at the OVC followed by a Surgery residency with concurrent Doctor of Veterinary Science (DVSc) in small animal surgery. She became board certified in small animal surgery (ACVS) in 2001 and has since been on faculty at the Ontario Veterinary College. She is an ACVS Founding Fellow in Minimally Invasive Surgery and a Founding Member of Veterinary Neurosurgical Society.
Text Dr. Lenz any feedback or questions Fibromyalgia and Magnesium: Exploring the Evidence and InsightsIn this episode of 'Conquering Your Fibromyalgia,' hosted by Dr. Michael Lenz, we delve into a literature review on magnesium and its potential impact on fibromyalgia. Dr. Lenz addresses a listener's question regarding the relationship between chronic fatigue syndrome and fibromyalgia, suggesting that these conditions may be variations of the same syndrome. The episode includes an in-depth review of studies investigating the correlation between magnesium levels and fibromyalgia, exploring how different forms of magnesium supplementation might affect clinical parameters. Key findings show mixed results, highlighting the complex and inconsistent nature of magnesium's role in fibromyalgia. Dr. Lenz also discusses the challenges of accurately measuring magnesium status and the importance of placebo-controlled trials in understanding the true impact of magnesium on fibromyalgia symptoms.00:00 Introduction to the Podcast00:35 Listener Question: Chronic Fatigue Syndrome vs. Fibromyalgia01:08 Understanding Fibromyalgia and Chronic Fatigue Syndrome03:51 Magnesium and Fibromyalgia: An Overview10:41 Clinical Studies on Magnesium and Fibromyalgia19:26 Discussion and Conclusion20:16 Final Thoughts and Call to Action Support the Show.A Fibromyalgia Starter Pack, which is a great companion to the book Conquering Your Fibromyalgia, is now available. Dr. Michael Lenz practices general pediatrics and internal medicine primary care, seeing patients from infants through adults. In addition, he also will see patients with fibromyalgia and related problems and patients interested in lifestyle medicine and clinical lipidology. To learn more, go to ConquringYourFibromyalgia.com. Remember that while Dr. Lenz is a medical doctor, he is not your doctor. All of your signs and symptoms should be discussed with your own physician. He aims to weave the best of conventional medicine with lifestyle medicine to help people with chronic health conditions live their best lives possible. Dr. Lenz hopes that the podcast, book, blog, and website serve as a trusted resource and starting point on your journey of learning to live better with fibromyalgia and related illnesses.
On this special Upgrade Spotlight episode of The Human Upgrade, you'll explore the science of NAD and its vital role in your cellular health with Dr. Nichola Conlon from Nuchido Laboratories. Learn how NAD supports energy production, cellular repair, and longevity. Dr. Conlon breaks down the latest research on NAD, explaining why levels decline with age and how to naturally boost them without expensive and uncomfortable IV treatments. Dr. Conlon breaks down innovative ways to enhance your NAD levels, reduce inflammation, and improve overall health and shares practical tips on maintaining high NAD levels through diet, lifestyle changes, and supplementation. You'll understand how these strategies can combat fatigue, brain fog, and aging symptoms, offering benefits for both physical and cognitive performance. Tune in to uncover the latest advancements in NAD research and how you can apply them to enhance your cellular health and well-being. Timestamps: 00:00:00 — 1: Opening 00:01:07 — 2: Introduction to NAD and Dr. Nichola Conlon 00:01:46 — 3: Understanding NAD and Its Functions 00:02:23 — 4: The Challenges of Boosting NAD Levels 00:05:31 — 5: The Science Behind NAD Decline and Aging 00:09:15 — 6: Clinical Studies and Evidence 00:14:35 — 7: Practical Benefits of Boosting NAD 00:19:17 — 8: Addressing Inflammation and Glycation 00:26:32 — 10: Big Pharma vs. Supplement Approach 00:30:10 — 11: Enhancing Bioavailability of Supplements 00:33:45 — 12: Impact on Chronic Conditions 00:37:05 — 13: Addressing Autoimmunity and Inflammation 00:44:00 — 15: Final Thoughts and Recommendations Sponsors: Nuchido | Go to Nuchido.com/Upgrade, or use code Upgrade10, for a 10% discount! Resources: Nuchido.com/Upgrade, or use code Upgrade10, for a 10% discount! Follow Nuchido on Instagram: @Nuchido Nuchido's Linktree: https://linkin.bio/nuchido/ Dave's Linktree: https://linktr.ee/daveasprey Dave Asprey's Book ‘Smarter Not Harder' is out now: https://daveasprey.com/books Follow Dave on Instagram: @Dave.Asprey Want to join The Human Upgrade Podcast Live? Join Our Upgrade Collective: https://www.ourupgradecollective.com/ Danger Coffee by Dave Asprey: https://www.instagram.com/dangercoffeeofficial/ Supplements by Dave Asprey: https://shopsuppgradelabs.com/ Own an Upgrade Labs: https://ownanupgradelabs.com/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, I sit down with Jill Schiaparelli, CEO of Avation Medical, to discuss their groundbreaking device, Vivally. Vivally is designed to alleviate overactive bladder symptoms through noninvasive tibial nerve stimulation. Jill explains how Vivally works by continuously monitoring and personalizing electrical signals to effectively target the tibial nerve. We cover the challenges of current OAB treatments and reassure the audience about Vivally's convenience and effectiveness. We'll also touch on how the device can be integrated into patients' lives with minimal disruption, instilling confidence in our audience.For more information, visit Avation website HERETimeline00:28 Introduction00:35 Understanding Overactive Bladder01:03 How Vivally Works01:39 Challenges with Current Treatments02:03 Innovations in Neuromodulation04:18 Vivally's Unique Features07:19 Patient Experience and Feedback16:32 Clinical Studies and Effectiveness19:29 Future Research and Real-World Data22:09 How to Access Vivally23:30 Conclusion and Final Thoughts
KCRW looks at barriers to accessing clinical trials for Black and Latino people. Plus, one cancer patient explains how his life changed after becoming involved in a trial. Folks who dislike both Donald Trump and Joe Biden make up 1 in 5 voters in swing states. How they go, so may the country. Oakland Mayor Sheng Thao, who already faced a recall, defended herself on Monday after the FBI raided her home. Her city is facing high rates of crime and homelessness. “The Big Cigar” (Apple TV+) follows Black Panther co-founder Huey Newton's 1974 escape to Cuba, aided by a Hollywood producer who disguised the plan as a film production.
KCRW looks at barriers to accessing clinical trials for Black and Latino people. Plus, one cancer patient explains how his life changed after becoming involved in a trial. Folks who dislike both Donald Trump and Joe Biden make up 1 in 5 voters in swing states. How they go, so may the country. Oakland Mayor Sheng Thao, who already faced a recall, defended herself on Monday after the FBI raided her home. Her city is facing high rates of crime and homelessness. “The Big Cigar” (Apple TV+) follows Black Panther co-founder Huey Newton's 1974 escape to Cuba, aided by a Hollywood producer who disguised the plan as a film production.
More than 60 years after a birth control pill was developed for women, there is still no similar federally approved drug for men. But promising results from a new gel for men might finally change that. Early results show it blocks sperm production after two to three months of daily use. William Brangham discussed more with Dr. Brian Nguyen. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders
Singer/songwriter and former pediatric clinical researcher Kieran James joins us to talk about his daughter's diagnosis, the importance of clinical trials, and how music gave him an outlet from the frustrations of T1D.Connect with Kieran:Website: www.kjsongs.comInstagram: https://www.instagram.com/kieranjsongsYouTube: Unspeakably Wonderful - YouTubeSpotify: https://open.spotify.com/artist/4xc7IsrdzVREtrZDe3XrXx Clinical Studies — Stanford Diabetes Research Center Research | Division of Endocrinology and Diabetes | Stanford Medicine The Discovery of Insulin: Twenty-fifth Anniversary Edition What to do next... Leave a review on Apple Podcasts Join the Half-Dead Pancreas Club Follow the Pod on Instagram Follow Colleen on Instagram Follow Jessie on Instagram Follow us on TikTok
Vet Life Reimagined brings guest, veterinary oncologist, Dr. Craig Clifford. About the guest:Dr. Craig Clifford graduated from Mississippi State University College of Veterinary Medicine and received an MS degree in Animal Science/Virology from the University of Delaware. In 2003, he became a diplomate of the American College of Veterinary Internal Medicine (Oncology). He is a medical oncologist and director of Clinical Studies at Blue Pearl Malvern in Pennsylvania.He is active in clinical research within a referral setting and serves as an advisory board member with both industry and non-profit foundations. He is a renowned oncologist who has authored/co-authored over 70 papers and book chapters. He is a frequent lecturer at major veterinary meetings in the USA and abroad. Dr. Clifford is a member of many committees, task forces, and medical exam review boards.In this episode, we discuss- how to implement clinical trials in any veterinary practice & the benefits- exciting updates in veterinary oncology: diagnostics & treatments- the reward of mentoring others in veterinary medicineResources:
In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable chats with Dr. Philip Bergman, known for his work on the Canine Melanoma Vaccine, Oncept®. Dr. Bergman shares his journey from considering a career in dairy practitioner to becoming a key player in the field of veterinary oncology. He talks about his experiences with human cancer research centers, the challenges he faced introducing new cancer treatments in veterinary medicine, and the importance of mentorship. Dr. Bergman also discusses the potential of treatments like checkpoint inhibitors. Get a glimpse into the evolving world of veterinary oncology, the collaboration between human and animal health research, and the practical challenges of making advanced treatments accessible. Note: This interview was recorded in November 2023. Since then, Dr. Bergman became the Director of Clinical Studies at Mars Veterinary Health, globally responsible for clinical studies. Transcripts are available at https://www.imprimedicine.com/podcast. To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/personalized-prediction-profile. Music Credit: Hazy by Beat Mekanik
In this episode, Dr. Art Mollen and Olivia Fierro take you through a bunch of head scratching topics. Some of them include the common misdiagnosis of shingles, clinical studies that have been going on for depression and what the updates are, and what you should do about high cholesterol among many other topics. Do you have a question you'd like answered on the show? You can email askdrartmollen@gmail.com to get your question featured in an upcoming episode. Watch this episode on YouTube!
What if your smart device could improve your nutrition? This show is brought to you by SmartCookie Media where we provide end-to-end podcast production and VIP Day marketing services. Book a complimentary content session and ask for our free podcast checklist here. After multiple health issues in his family, Ari knew he needed to dedicate his life's work to the health care system — or should we say 'sick care system.' Ari worked with the cellular team at Nokia when they installed the step counter to phones. So when he saw how gamifying strategies started to change the health sector and patients lives — he knew he had to get involved. Ari Tulla is the CEO and co-founder of Elo Health. They are taking the Smart approach to nutrition that fills your nutrient gaps based on your activity data, wearables, and biomarkers for exact personalization. With the help of a science team, a medical team, and AI, Elo has over 389 million combinations and 100 active ingredients to give you precise and personalized supplements for your exact needs. Get Weekly Tools to Build Your Business (for free!): The Entrepreneur's Toolkit Connect with Nicole: Nicole Schmied Linkedin; @Nicole Schmied Get Your Data-Driven Marketing Strategy: SmartCookie Media FREE: Content Strategy Session Visit: Elo Health LinkedIn: Ari Tulla Have a story to tell? Signup here: www.serialentrepreneurshow.com
Show Notes: Candy Gunther Brown, professor of Religious Studies at Indiana University and co-founder of the Global Medical Research Institute, discusses empirical research on prayer for healing, her own miracle story, and yoga in public schools. Candy has held her current position since 2006. She has been studying mostly Christianity in the United States and globally since 2006, however, her specific focus on healing practices has led to including world religions in her studies. She initially focused on the history of Christianity, but later realized that much of the growth of Christianity was in areas of Pentecostal and charismatic Christianity, where people pray for God to heal them when they are sick. This led her to explore questions about modern medicine's effects on praying for healing, particularly in contemporary practices. Clinical Studies on the Healing Effects of Prayer Candy has conducted field work in Mozambique and Brazil, working with medical doctors and researchers to develop clinical studies on the effects of prayer, and has published significant findings in peer reviewed medical journals. Dialogue with patients led Candy to explore the world of complementary and alternative medicine, which has become more mainstream medically than some of the prayer practices. Her research has taken on different emphases over the years, including being an expert witness in court cases over yoga in public education. One of the best courses she took at Harvard was constitutional law, which helped her consider constitutional issues involved with yoga and meditation in public schools from a legal perspective. A Personal Experience with Healing through Prayer Candy's personal journey also led to new academic and personal questions, as she met someone she met while at Harvard during graduate school and had new experiences that opened up new academic and personal questions. The Global Medical Research Institute (GMRI) was founded by Carol and her husband Josh, a brain scientist at Washington University in St. Louis. After Josh's untreatable terminal brain tumor was diagnosed, they began investigating the power of prayer for healing. They found that prayer can lead to significant improvements in various aspects of life, including hearing, vision, and emotional well-being. When Josh recovered, they decided this was an area that should be studied more consistently and in more depth, so they founded the GMRI. Healing through Prayer and the Placebo Effect Candy discusses the comparison of healing through prayer and the placebo effect, which is limited in its impact; it often sees a reduction in pain but does not provide significant changes in organic conditions. She shares the results of studies on healing through prayer, and how proximal intercessory prayer, or proximal intercession, has been shown to result in substantial improvements. For example, a subject in Mozambique was able to read fine print on an eye chart after five minutes of prayer. This is a much larger improvement than most placebo effects or related mind-body effects. Scientific research shows that people are convinced that they are healed through prayer to such a degree that it has been a major factor in the growth of Pentecostal and charismatic Christian movements worldwide. This belief has been a major factor in the growth of these movements, with approximately 635 million Pentecostals and charismatics globally, and around 2.4 billion Christians. Research on Intercessory Prayer Candy talks about research that took place in Mozambique where they were conducting studies on distant intercessory prayer. She discusses the difficulties they encountered and surprising results when conducting studies with people from different branches of christianity. In one study, researchers prospectively recruited every individual who was brought up in communities with little technological connection. They tested them with equipment and recorded all results before and after prayer, regardless of whether they reported improvements or not. The effect had to be large enough and common enough to find an actual statistical difference. The study found statistically significant improvements in those who received prayer. Cindy goes on to explain that prayer is a growing force in areas with limited access to medical care and basic necessities. She mentions research that was conducted in collaboration with 17 other scholars in Pentecostal movements worldwide. The findings suggest that healing and deliverance practices are the driving growth edge for these movements, as people in need of medical care and food security often lack the resources and support they typically receive. This finding underscores the importance of further research in this area. A Personal View on Proximal Prayer Healing Candy discusses the impact of proximal prayer on healing. She has been researching this topic for 20 years and has come across cases of fraud and falsification, however, she believes that these cases are less common than people think. She also mentions cases where people believe they got healed through prayer but also have other factors that caused them to recover, such as self-limiting conditions or mobility issues. She allows people to evaluate the data from the studies for themselves and acknowledges that some cases are hard to come up with a medical explanation for what took place, and she shares a few stories of healing, including a blind woman whose sight was restored. One studies she cites states that 73% of U.S. doctors believed that miracle healing had taken place. Alternative Medical Practices and Constitutional Implications One of Candy's research projects focused on alternative medical practices and constitutional implications. She was asked to evaluate the legal challenge over yoga in a public school district in San Diego, California. The yoga program was promoted by a Hindu guru who believed yoga was becoming one with God. However, parents, including Christian, Hindu, and atheist parents, were concerned about the teachings and wanted a secular education for their children. Candy's book explores the global cross fertilization of yoga programs, from India to the United States. Candy shares results from various studies on yoga or mindfulness practices. Influential Harvard Professors and Courses Candy shares her fond memories of her time as a professor, including being invited to a professor's house for dinner, attending a core curriculum class, and working with Owen Gingrich, a professor with a Mennonite background. These personal connections have been significant in her career, as she has been invited to his house for dinner parties and conducted research for him while traveling in the Philippines. Other memorable experiences include studying Latin 3, listening to Marjorie Garber's Shakespeare lessons, learning about Michelangelo, and writing a senior thesis. She also had significant experiences through Phillips Brooks House, particularly working with the refugee youth summer enrichment program (RISE) and the Harvard Radcliffe Christian fellowship. Timestamps: 05:19 The power of prayer in healing with a neuroscientist and religion professor 10:44 The effectiveness of prayer for healing 16:07 Clinical trials and prayer with a focus on ecological validity 23:26 Healing and spiritual practices in Pentecostal movements 28:10 Healing and divine intervention through prayer 32:08 Yoga in public schools and belief in miracles 36:56 Secularization of yoga programs and their impact on mental health Links: Website: https://www.globalmri.org/ Book: https://www.amazon.com/Debating-Yoga-Mindfulness-Public-Schools/dp/1469648482 Article: huffingtonpost.com/candy-gunther-brown-phd Article: psychologytoday.com/blog/testing-prayer CONTACT University: https://religiousstudies.indiana.edu/about/faculty/brown-candy.html LinkedIn: https://www.linkedin.com/in/candy-gunther-brown-a28a3232/ Twitter: https://twitter.com/candygbrown Facebook: https://www.facebook.com/people/Candy-Gunther-Brown/100063617970195/
In this instalment of The G Word, our guests engage in a compelling discussion centred around a recently published paper that supports the integration of whole genome sequencing into standard cancer care. Our guests shed light on the transformative potential of combining health data with whole genome data. Discover how this innovative approach empowers doctors to deliver more personalised and effective care. Our guests delve into the findings of a landmark national study, unravelling the significance of identifying inherited cancers for patients and their families. The episode explores not only the scientific advancements but also the real-world impact on individuals facing a cancer diagnosis. Our host Naimah Callachand is joined by Dr Nirupa Murugaesu, a Consultant in medical oncology at Guy's and St Thomas' NHS Foundation Trust, and the Principal Clinician for Cancer Genomics and Clinical Studies at Genomics England. And by Professor Sir Mark Caulfield, a Professor of Clinical Pharmacology at Queen Mary University of London, and who previously served as Chief Scientist for Genomics England and was instrumental in the delivery of the 100,000 Genomes Project. "In cancer we were sequencing sections of the tumour and comparing them to DNA inherited from your mum and dad, and that comparison allows us to work out what is driving the cancer, what may be affecting its potential for treatment and how we might choose treatments for patients. So this is a real opportunity to create precision cancer care." You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/Whole-genome-sequencing-in-cancer-care.docx Naimah: Welcome to the G Word. What does it mean if we can test for inherited genes? Nirupa: It can influence how their cancer is treated. So it means that there may be certain types of therapy that are available if they have a specific inherited cancer gene, number one. It also can impact in terms of preventing further or other cancers related to those genes, and it may impact the type of surgery they have, and also the type of overall cancer treatment. And then finally, if they have got an inherited cancer, then, as I mentioned before, it may impact in terms of testing and screening for their family members. Naimah: I'm your host Naimah: Callachand. Today, I'm delighted to be joined by Dr Nirupa Murugaesu, who's a consultant in medical oncology at Guy's and St Thomas' NHS Foundation Trust, and the principal clinician for cancer genomics and clinical studies here at Genomics England. And Professor Sir Mark Caufield, who's a Professor of Clinical Pharmacology at Queen Mary University of London, and who previously served as chief scientist for Genomics England and was instrumental in the delivery of the 100,000 genomes project. Today, Mark and Nirupa are going to discuss key findings from a recent paper that's just been published in Nature. If you enjoy today's podcast, we'd really love your support. Please like, share and rate us on wherever you listen to your podcasts. Now, let's get into the interview. So first of all, Mark, I wondered if you could give me a bit of background on the 100,000 genomes project? Mark: So the 100,000 genomes project started in July 2013 following an announcement by the then prime minister, David Cameron, that the UK would be the first health system in the world to sequence 100,000 whole genomes, which is as much as you and I can read of the genetic code. In the case of cancer, which we focused on here, in cancer we were sequencing sections of the tumour and comparing them to DNA inherited from your mum and dad, and that comparison allows us to work out what is driving the cancer, what may be affecting its potential for treatment and how we might choose treatments for patients. So this is a real opportunity to create precision cancer care. Naimah: And Nirupa, can you tell me what the 100,000 genomes project meant for these patients with cancer? Nirupa: I think, firstly, we're very grateful for all of the participants in the programme, because what it's allowed us to do is to look at the data as a whole, and having all of that sequencing data alongside clinical information has been incredibly valuable, it has also developed the infrastructure for testing. And really I think for patients with cancer, they participated in this programme as a research project, and unusually for a research project these results were returned back to treating clinicians to clinical teams, if there may have been a result that would impact or change their management. But I think, importantly, what it enabled is the implementation of standardised cancer testing in the NHS, and really enabling that for a wider range of patients, not just those that participated in the project. And because of patients participating, this then allowed all of the data to be stored in a single place, and this has been incredibly valuable for clinical academics and researchers. Naimah: And can I ask what specific types of cancer that were looked at in 100,000 genomes project? Nirupa: Again, the project was set up such that we allowed a number of different types of cancers to be sequenced and, therefore, very permissible, because we also wanted to ensure that some of the less common and rarer cancers were also sequenced and, as you would expect, more of the common cancers as well. In addition, I think the opportunity to sequence paediatric cancers, as well as haematological malignancies, or blood cancers, was also key as part of the cancer programme. Here, we focus on the solid cancers, but obviously there was a much wider range of cancers that were sequenced. Naimah: And next, can we move on to talk about the findings of the study? Nirupa: I think, firstly, by undertaking sort of a pan-cancer analysis, it really gave us an overview of the number of target and genes that were found to be actionable. And what I mean by that is that they have a, well, clinically relevant, and we can see that in certain cancer types, such as in brain cancers, in colon cancers, lung cancers, there were within the genome sequence more than 50% of these cancers had something that was what we would call actionable. So there was a mutation in a gene for which this would influence treatment. And as we started to look more across the entire cohort of patients, you can really get an idea of the fact that the more that we sequence, and the more comprehensive the testing is, the number of different types of mutations that we were able to discover. Naimah: And when you mentioned that these findings were actionable, what does that mean? Nirupa: So what that means is that has an impact in how the patient will be managed and treated. It may influence, firstly, the type of surgery they have, it may influence the type of cancer treatment that they receive. And all of this, I suppose, comes back to the point that Mark mentioned, of precision oncology, so we more precisely treat patients based on their individual cancers. Naimah: And could you give me some examples of maybe some of these genes that were found in the study that were actionable? Nirupa: Yes, so the types of genes also matter, or the type of mutations. So some of them were in known cancer genes, and if you have, for example, a mutation in lung cancer, in a gene called the EGFR gene, we know that there are cancer therapies that can be provided that target specifically this mutation. So that's one example, and this is quite well characterised and understood in oncology care. But what we were also able to do with whole genome sequencing, is identify different types of mutations that are harder to characterise routinely. And these are often included things that we call pan-genomic markers, where we can see what the mutational landscape is of the cancer, the different patterns of mutations can be gleaned from this, and often this can then give you an idea of the underlying biology of the cancer. But importantly, in certain types of cancers, such as high grade serious ovarian cancer, it highlights which patients may have a particular marker that means they may or may not benefit from a particular type of therapy. So in this particular case, the class of therapy is called PARP inhibitors. Naimah: And how did the study compare to other similar stuff studies in the genomics area? Nirupa: That's a really good question, and I think we looked at this from other large sequencing endeavours, such as the ICGC, TCGA, so these are big studies where have been whole genomes sequencing. Also within the Hartwig Institute in the Netherlands, they've also undertaken whole genome sequencing for cancer patients. And what we were able to identify is that the patterns of mutations were as expected, we found, you know, a lot of similarities. I think the difference, the main difference is not just identifying the type of mutations across the different cancers. But the fact that we were then able to look at the longitudinal outcome, and correlate some of these genomic markers with outcomes related to both therapies, as well as survival impact of having certain mutations in terms of prognosis. Naimah: Mark, do you have something you'd like to add there as well? Mark: Yeah. So one of the things that we did in the 100,000 genomes project, was to evaluate the best way of measuring the whole of your or my genetic code. And we discovered that very early on that if you expose the tumour to a preservative, which is called formalin which keeps the tumour preserved, that actually you could get quite a number of misleading findings. And so to address that, the distinctiveness from former programmes, such as Nirupa mentioned, like the Cancer Genome Atlas, is that all of the tumours that we studied in this paper were actually produced under fresh tissue conditions, and have not been exposed to a preservative. And that means that what we have is a really accurate reflection of the variation within the tumours. And the other thing about this particular resource is it's the biggest resource. We were able to look at 13,000 people with solid tumours, but we also had blood cancers and other cancers which also feature of this paper. And a further remarkable thing about this is early on, Nirupa and the team and I decided that we would longitudinally life-course follow the patients and by accruing data from multiple sources in the health system. So, every attendance at the hospital, what chemotherapy was had, we've been able in this paper to recapitulate signatures that clearly show that certain mutations are harmful. And many of the findings that we've made are absolutely, if you look at the survival of patients particularly, you can see almost identical patterns to those in clinical trials. What this means is that by the really rich data set which is now many billions of clinical data points on these patients, we can actually look for long-term signals of benefit and harm that perhaps would not be detected by a clinical trial that might last for six months or a year. So this is a really valuable resource, and the really great thing is we can use what's called real-world data, which is where we take routine health data, and we can recapitulate the findings from tightly controlled clinical trials. And I think that's quite an important finding. Naimah: That kind of brings me onto the next question, Mark, where I want to talk about the value and benefit of genomics sequencing for cancer patients. I wondered if you could expand? Mark: Well, what we know from one of the genomics medicine centres which were regional hubs, is that they use the information that we return, that Nirupa outlined earlier in a report, for 25% of their patients. Which means that they concluded having evaluated that as the clinical team locally, that there was something the patients could benefit from. Now, what we think is this makes the case for certain cancers being part of the national genomics test directory whole genome sequencing, but it's still the case that the majority of testing for cancer is now very large focused panels that are focused on specific gene features. But in some measure, this work is also able to reassure us that those gene features are the right ones to focus on, so this work has been very useful in that respect, even where the NHS today cannot make the financial or clinical case for using whole genomes in specific cancers. So I think the programme's made a massive difference. The biggest thing it's done for patients, which Nirupa was very actively involved in, is it's allowed us to create a national genomics test directory. So when we started this, cancer genomic testing was completely random and would vary from one postcode to another, one hospital to another. And what Nirupa and the cancer team created is a national cancer genomic test directory, which now means that standard of care, that's the basis for reimbursement, and it's available across the landscape of 56 million people. And given that one in two of us will have cancer, this is a massive advance. Naimah: Yeah, you've really highlighted the impact of having access to such a large database. And I just wanted to ask as well, what are the challenges associated with implementing routine whole genome sequencing into clinical care? Nirupa: I think as with all of these things when implementing something new within a healthcare system, it requires a level of education, upskilling and also, as Mark has touched on, how we handle the tumour tissue, so that it's handled in a genomic-friendly way to enable the best results if you like, because we want to ensure that their DNA is not damaged so that we can get accurate read-outs on the results. So there are challenges and there is also cost implications in weighing up the pros and cons. And I think what we were able to show, and by undertaking this sort of pan-cancer analysis, is where there are those cancer type where there is a real need for whole genome sequencing, or where it can be justified, because there are a number of different types of mutations both within the tumour. And also from a blood sample that is also taken, so this is your constitutional DNA, so this is if there is a risk of an inherited cancer. So we are able to pull together all of this information, and obviously that's important, not just for the patient, and their management, but also for family members. So I think really what this shows is that where you have to identify many of these different types of mutations, whole genome sequencing enables that through a single test. Naimah: Mark, would you like to add something else there? Mark: One thing I think which Nirupa's very much part of, is the distinctiveness of the Genomics England approach has been to involve the NHS at every stage. Now, what that means is we estimate that at the peak of the 100,000 genomes project, 5,000 frontline NHS staff touched the project at some point in their working week. What that does mean is that Nirupa and the cancer team could realign the cancer tissue handling pathways. But it also meant that we were able to upskill the frontline workforce, such that at the end of the programme, when we produced a genomic test directory, they were really up for it because they did not want all the hard work they'd put in to stop. And so what we've done is produce the national test directory within five years of starting, that wasn't a deliverable for the project, but it was nonetheless obvious to all of us working in it, including NHS England, that there needed to be service transformation, and we've managed to effect it. Now, if you look at other settings where perhaps Nirupa and I might have a research team, we might do it some distance from the health system, it would be in the health system, but not with the health system, then it takes between nine and 16 years to get these things into clinical practice. And that was achieved here in five years. So there is a lesson from this, the cancer programme particularly, because the cancer programme testing was very limited when we started, but you can take an entire workforce on a journey and leave them with the legacy of an entirely transformed system for patients. And thankfully because we got, Nirupa and I, the NHS to agree to reimburse for the testing directory being used, we have eliminated a lot of randomness that was in the system previously. So it's quite an important advance in that respect, and it really does show in the beautiful work that Nirupa was describing exactly how you can use this information to change an entire system. And the NHS is not the easiest system to change in the world. Naimah: Nirupa, you mentioned the findings show that there was potentially inherited genes. Can you tell me what does that really mean for patients, if we're able to diagnose these inherited genes sooner in life? Nirupa: It can influence how their cancer is treated, so it means that there may be certain types of therapy that are available if they have a specific inherited cancer gene, number one. It also, can impact in terms of preventing further or other cancers related to those genes, and it may impact the type of surgery they have, and also the type of overall cancer treatment. And then, finally, if they have got an inherited cancer, then, as I mentioned before, it may impact in terms of testing and screening for their family members. And that's really key as well, because this means that their cancer can be diagnosed, if they do develop a cancer, because they're being monitored, because it's much more targeted, their approach in terms of screening for a particular type of cancer, they can potentially have their cancer treated much earlier. Or even better, before it becomes what we call an invasive cancer but at the pre-cancerous stage. So this has huge implications, and what we're finding actually with more and more testing – and this is not just... our study was consistent with other studies that have been published – is that when you undertake more routine testing, then you are able to identify this. It is not common amongst the population, but in those patients where it is relevant, it really can impact their care. Naimah: Mark, do you have something to add there? Mark: Well, I think Nirupa's just highlighted a really important point. So to bring that into a little bit more ways of which people listening to this can relate to it, we have a family where there was a women who had no family history of breast cancer, she developed breast cancer, and in the tumour we found that she had a BRCA 2 mutation. We also found that she'd probably acquired that or inherited it, we don't know. That for her meant that she could enter the Olympia trial, which was running at the time, which Nirupa alluded to earlier, was a study of PARP inhibitors. But without that genetic makeup she'd never have got into that trial, and she probably wouldn't have been tested for BRCA at that time in the NHS because she had no family history, I think that's probably right, Nirupa. And then there was a family-wide consequence for that, because she had a brother and son, and she also had a daughter, and the daughter was under 30 at the time and underwent BRCA testing and was BRCA 2 positive. But she has the opportunity now to enter intensive breast screening from the age of 30, and that's what's happened. And her brother, and this is the lady who had the breast cancer, her brother and her son may be at risk of prostate cancer, so they can consider testing. So Nirupa makes a really important point, that when people have inherited a previous disposition to cancer, that can have a family-wide impact. And one test in one family member can open the doors to opportunity for others to understand their risk and to be screened more actively and intensively, hopefully with meaning that if they do develop cancer it will be detected very early, or maybe we can just prevent it altogether. Naimah: Thanks, Mark, a really good example of the impact that this testing has had. I just wanted to touch back on your point, Mark, that you'd made about real-world data. And I wondered actually, Nirupa, if you could kind of explain to me why it's important to link real-world data to the genomic data? Nirupa: Yeah. So I think the work we've done here really does emphasise this, because when we refer to real-world data, we're talking about different types of healthcare data across the population. And we had the opportunity to link the genomic data to a number of key data sets that are curated by the cancer registry, the national cancer registry database. And this includes things like all of the population base systemic anti-cancer therapy, so we know that for each of the participants the type of cancer therapy they receive, and also, as Mark has mentioned previously, the hospital episode. So when patients needed to be... we can see their data in terms of admissions, investigations, and so on. And these are really valuable data points, because you get an indication of when patients may have had to then have further testing, or if there is a risk of recurrence and importantly survival data, because a lot of this has been, in terms of a lot of the cancer genes have been well characterised and tested. But what we were able to do here at a pan-cancer level on a large cohort of patients over a period of time, is to look at if you had a particular mutation, what is the impact of that in terms of outcome for a particular cancer type, and even more broadly, on a pan-cancer level? And actually, as this type of data accumulates, I think the real value, and if you've got a larger number, you know, what is the value for patients who've participated in this programme going forwards, is that as that data accumulates and the numbers go up, we are able to then ask more detailed questions. What is the impact of a particular type of mutation, or a particular type of variant within a gene? And, importantly, what happens when you get a different sequence or a combination of genes? And how does that impact? And this, I feel, is the way that we are going to move more towards precision oncology, because we are beginning to understand the cancer in more detail, how it is going to behave, and then try and tailor therapies accordingly. Naimah: And Nirupa, I wondered if you could tell me as well if the findings from this study have benefited directly those patients that were involved in the 100,000 genome project? Nirupa: It has benefited some of the patients because, as Mark has mentioned, there are findings that we weren't expecting in terms of potentially inherited cancers and, therefore, this has had implications. The way that the project was set up from the outset, is that we were obtaining tumour samples from patients who had not received any previous cancer therapy. And what this meant is that this was predominantly in patients, so they were treatment naïve with early stage disease that were having surgery to treat their cancers. And as such, what we know is that fortunately most of those patients did not require further therapy, because their cancers were treated successfully with surgery. But what it did tell us, and what it's really highlighted, is the number of important genes that were identified. And so whilst it may not have impacted patients directly, it's enabled us to study the biology of the different types of cancers, how they behave, along with the longitudinal clinical data. But what it is doing now, is through the national test directory through the genomic medicine service, is enabling testing for patients that unfortunately now have more advanced cancers, but where these genomic findings are more likely to impact directly in terms of therapy. So, for instance, as we've mentioned, the ability to have whole genome sequencing for patients with high grade serious ovarian cancers, means that this will impact the type of treatment they have. And this also was the tumour type where we found the highest number of patients with BRCA mutations, so we have a potential inherited risk of a cancer as well. So now what we have learnt and the infrastructure that we have developed has enabled this to have a real impact, not just for patients in the project now, but wider within the NHS. Naimah: Mark, would you like to add something else there? Mark: I think Nirupa's encapsulated it very well. There were a range of benefits, so I mentioned earlier that in one centre 25% we have evidence got a benefit for their treatment for their cancer in some way shape or form. So an example to what there might be is that some people got a medicine they wouldn't have received from routine care, and that might have been licensed for the treatment of that tumour, but it wouldn't have been the first line treatment choice. Some people got medicines that they wouldn't have got because we don't normally associate using that medicine with that cancer, but they had a signature that showed that they were very likely to benefit. Quite high numbers got an opportunity to get into a clinical trial, which is really important because if you look, over 50% of global oncology trials now have some kind of biomarker or diagnostic, or something like this alongside, what better than to have a comprehensive inventory of the variants and the cancer, and to be able over time to use that library to understand better the treatment course of that patient. And that's what I think a whole genome adds, rather than the single, look at a single part of the genetic makeup. And then finally, some had lots of mutations, really high rates of mutations, and maybe they should receive specific advance therapies, like immunotherapies. Or alternatively, they had a feature in their genetic makeup which it looks like they inherited, as Nirupa absolutely correctly said earlier, these people need to be followed-up and they need more intensive screening, because this is how you detect cancer at an earlier stage. And the final way people benefited is we could detect genetic changes in their DNA that meant that if they were exposed to certain medicines, they were likely to suffer harm. And there's a particular, two medicines, 5-fluorouracil capecitabine, where possibly about 5% of people will need either a reduced dose or a completely different medicine, because it will be very harmful. And so this is about getting the right medicine to the right patient first time, and getting the right outcome for that patient downstream. And I think, you know, Nirupa's encapsulated it perfectly, there's a whole range of benefits that the patients can accrue from this. And I think we should probably, Nirupa, say that people were quite cynical when we started, about what it would be that you would get over and above, for example, the cancer genome map that's at the international cancer genome consortium. And, you know, I'd had leading cancer scientists in Britain say, "Oh well, we've discovered it all, there's nothing to find here." And I think what this paper shows is that's not entirely true. Nirupa: I would agree with that Mark, but I would also probably add that it highlights the value of having a large data set alongside that clinical information. And what we were also able to do, is whilst we very much talked about what were the gene targets that had a direct impact or genomic markers that impact care now, for which there is an approved therapy. What we've also been able to do through this analysis, is actually highlight the number of mutations that have been identified for which there is a licence therapy in another cancer type, but not in that particular cancer type. And what that means, is that specially now, as we have more and more biomarker-driven therapies, I mean, if we look at that compared to when the project started and now, that has increased dramatically. And what that means is then there are sort of licensed medications that actually can be used in non-licensed indications via a clinical trial, via these very, you know, these basket studies which are across cancer types and are actually based on different types of molecular markers. And really, we're able to show this at a pan-cancer level across the 13,000 tumours through the results from whole genome sequencing. Naimah: You've both kind of touched on this throughout and, you know, we've talked about the development of personalised medicine. And where do you see the future of cancer treatment in the next five years? Maybe, Nirupa, we can go to you first? Nirupa: That's a very good question. I think and what I hope is that with more comprehensive and equitable and standardised testing for patients, especially within the NHS, that this will enable more personalised and targeted therapy alongside, you know, systemic chemotherapy. And as well as that, better selection of patients that are likely to benefit from the newer immunotherapies. And also where sequencing is very exciting, is that once we begin to understand more about the individual tumours, you know, going forwards there are a number of cancer vaccine trials, and the aim of those are to have specific vaccines that are going to target an individual's tumour. So I think in the next five years, this is I think a very exciting space, I hope so, because we need to keep doing more in the space for our patients to try and improve therapy and precision oncology for them. Naimah: And Mark, do you have anything to add to that point? Mark: I think Nirupa's right, that there are new therapy extractions coming on, vaccination's one way. But I think that what will become clear is whether we can use any molecular mechanisms for early detection of cancer. The battleground here is that we all too often detect cancer late, when it's already outside of the organ it originated in and may be spread in other parts of the body. It's very hard to effect a cure, almost impossible in that setting. But what if we could detect cancer earlier? And then what if we could place a whole genome or detailed molecular characterisation alongside that? And then, as Nirupa suggested, give someone a vaccine tailored to their tumour that would eliminate it. The real problem is all too often we detect cancer late, so maybe some of these new molecular diagnostics, such as cell-free tumour DNA will usher in an era of early detection. And one of the things, and particularly before we did this project but also up until the beginning of the last decade, there were very few good biomarkers of cancer that were usable in the health system. So we have for the first time opened the vista of having early detection, if we combine early detection with detailed molecular characterisation, possibly a whole genome, possibly another test, then I think we really can usher in the era of precision medicine. And so I think Nirupa's absolutely right, there will be new treatments, there always will be, but what we have to do is to get detection at an earlier stage. Naimah: We'll wrap up there. Thank you to our guests, Dr Nirupa Murugaesu and Professor Sir Mark Caulfield for joining me today. If you'd like to hear more about this, please subscribe to the G Word on your favourite podcast app. Thank you for listening.
Data on beauty products can be both exciting and confusing. Dr. Love and Ian sit down with Paul Baek, founder of MATTER OF FACT, to learn about the brand's clinical commitment while explaining the differences in clinical studies. This episode unpacks what the clinical numbers on beauty packaging mean, how to interpret those numbers for yourself, and more about product formulation, including ingredient stability and patents. Hosted on Acast. See acast.com/privacy for more information.
Join your favorite Psychic Mediums, Nicole, Kristin and Glenda,
https://letsgobrandongreen.com/real-time-voice-analyzer-covid-detecting-app/Chapter 1: Introduction [0:00]Introduction to the podcast and guest, Tim Flatt.Chapter 2: The Birth of the App [5:00]Tim Flatt discusses the origins and purpose of the Real Time Voice Analyzer.Chapter 3: Science and Technology [10:00]Delving into the AI algorithms and the role of vocal fold sounds.Mention of Dr. Singh's foundational research.Chapter 4: App Usability and Benefits [15:00]Comparison to rapid tests, cost-effectiveness, and speed.The non-invasive nature of the app and its global availability.Chapter 5: Clinical Studies and Accuracy [20:00]Discussion on the clinical studies conducted in various countries.The app's accuracy and its potential in the future.Chapter 6: Marketing and Future Prospects [25:00]Grassroots promotion approach, including podcasts.The potential for the app to grow and its significance in the current health climate.(Note: The timestamps are just placeholders and would need to be adjusted based on the actual video length and content distribution.)Tim Flatt CEO of Real Time Pain Relief explains his revolutionary new AI Covid Detecting AppSupport the showLETS GO BRANDON GREEN PODCAST - https://letsgobrandongreen.com/
To access full episodes and our conference library of 200+ fascinating psychology talks and interviews (with certification), please visit: https://twumembers.com. Embark on a profound exploration of consciousness with Mark Solms, Anil Seth, Iain McGilchrist, and Donald Hoffman in this captivating compilation. Delve into the perplexing question of how conscious experience emerges from the intricate dance of neurons and synapses, challenging conventional notions. Join these esteemed minds as they unveil the brain's role as a predictive engine, crafting our perceptions instead of passively processing external inputs. Traverse discussions on perception, time, emotions, and the intricate interplay between matter and consciousness. Discover the universe of creativity and resistance shaping our reality. Engage in conversations about the deep connections between life, intelligence, and consciousness, gaining insights into our existence as both individuals and integral parts of the broader cosmos. --- Bios Iain McGilchrist Dr Iain McGilchrist is a Psychiatrist and Writer, who lives on the Isle of Skye, off the coast of North West Scotland. He is committed to the idea that the mind and brain can be understood only by seeing them in the broadest possible context, that of the whole of our physical and spiritual existence, and of the wider human culture in which they arise – the culture which helps to mould, and in turn is moulded by, our minds and brains. He was formerly a Consultant Psychiatrist of the Bethlem Royal and Maudsley NHS Trust in London, where he was Clinical Director of their southern sector Acute Mental Health Services. You can keep up to date with his work at https://channelmcgilchrist.com. Anil Seth Anil Seth is Professor of Cognitive and Computational Neuroscience at the University of Sussex, and the Co-Director of the Sackler Centre for Consciousness Science. He is a Wellcome Trust Engagement Fellow, and a Senior Fellow of the Canadian Institute for Advanced Research. Professor Seth is Editor-in-Chief of Neuroscience of Consciousness, sits on the steering group and advisory board of the Human Mind Project, and was President of the British Science Association Psychology Section in 2017. You can keep up to date with his work at www.anilseth.com. Donald Hoffman Prof. Donald Hoffman, PhD received his PhD from MIT, and joined the faculty of the University of California, Irvine in 1983, where he is a Professor Emeritus of Cognitive Sciences. He is an author of over 100 scientific papers and three books, including Visual Intelligence, and The Case Against Reality. He received a Distinguished Scientific Award from the American Psychological Association for early career research, the Rustum Roy Award of the Chopra Foundation, and the Troland Research Award of the US National Academy of Sciences. You can watch his TED Talk titled “Do we see reality as it is?” and you can follow him on Twitter @donalddhoffman. Mark Solms Professor Mark Solms is best known for his discovery of the forebrain mechanisms of dreaming, and for his pioneering integration of psychoanalytic theories and methods with those of modern neuroscience. He holds the Chair of Neuropsychology at the University of Cape Town and Groote Schuur Hospital (Departments of Psychology and Neurology). His other positions have included: Honorary Lecturer in Neurosurgery at St. Bartholomew's & Royal London School of Medicine, Director of the International Neuro-Psychoanalysis Centre, London, and Director of the Arnold Pfeffer Center for Neuro-Psychoanalysis at the New York Psychoanalytic Institute. Professor Solms' books include: Clinical Studies in Neuro-Psychoanalysis (winner of the NAAP's Gradiva Award Best Book, Science Category in 2001), The Brain and The Inner World (2002), and most recently: Hidden Spring: A Journey to the Source of Consciousness (2021).
Today, we have the pleasure of welcoming Jen Scheinman MS, RDN. You will quickly see that she is a true authority in the realm of Integrative and Functional Nutrition as she dives into the scientific intricacies of a process called mitophagy and equips us with some valuable tools for inducing this very important process. Hint: it all goes back to Urolithin A (Mitopure). So, get ready for an amazing episode! Topics: 1. Key Biological "Hallmarks of Aging" and the Role of Mitochondrial Health - Explanation of Aging Hallmarks - Significance of Mitochondrial Health in Aging Process 2. Addressing Declining Mitochondrial Health - Strategies to Improve Mitochondrial Function - Importance of Lifestyle Factors 3. Understanding Mitophagy and Its Impact on Health and Longevity - Definition and Mechanism of Mitophagy - Benefits of Mitophagy for Longevity 4. Urolithin A: Discovery and Characteristics - Origins and Discovery of Urolithin A - Properties and Effects on Health 5. Exploring Postbiotics - Definition of Postbiotics - Role of Postbiotics in Gut Health 6. Connection Between Urolithin A and the Gut Microbiome - Relationship with Gut Microbiota - Challenges of Obtaining Urolithin A from Diet Alone 7. Benefits and Clinical Studies of Mitopure - Who can Benefit from Mitopure? - Overview of Clinical Research Findings - Expected Effects of Mitopure Usage 8. Expansion from Nutrition to Skin Health - Evolution of Product Line - Research and Findings in Skin Health 9. Diverse Health Areas Explored with Mitopure - Investigation of Mitopure's Impact Beyond Muscle Health - Current and Future Research Directions Thanks for tuning in! Visit the shop page on synthesisofwellness.com purchase Timeline Nutrition's products, or go straight to their website by clicking the link here and use code CHLOEP for 5% off! If you liked this episode, please leave a rating and review or share it to your stories over on Instagram. If you tag @synthesisofwellness, Chloe would love to personally thank you for listening! Follow Chloe on Instagram @synthesisofwellness Follow Chloe on TikTok @chloe_c_porter Thanks again for tuning in! --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support
Noelly Michoux, Imen Jerbi and Dr Carlos Charles are the co-founders of 4.5.6 Skin on a mission to address the research equity gap for deeper skin complexions in a $140 billion global beauty market. Combining a personal skin journey, and expertise in pharmacy, cosmetics and dermatology, 4.5.6 Skin focuses on melanin-rich skin and eliminating the ‘one-size-fits-all' approach in skincare science. Tune in for more!If you enjoyed this episode, please make sure you like, subscribe, leave us a review and share with anyone you know who will love it too! Founded Beauty is available on all podcast platforms and we release new episodes every Monday and Thursday so be sure to follow the podcast to be notified. We really appreciate every single listen, share, and review. It goes such a long way and helps us reach new listeners. Follow Akash, Noelly, Imen and Carlos: Akash Mehta: @mehta_a Fable & Mane: @fableandmane www.fableandmane.com Noelly Michoux: @noellychouxxImen Jerbi: @imenwsmDr Carlos Charles: @albertocacha4.5.6 Skin: @456skinwww.456skin.com Follow us on Instagram @founded.beauty and TikTok @foundedbeauty. For more information about Founded Beauty, please visit www.foundedbeauty.com #foundedbeauty Hosted on Acast. See acast.com/privacy for more information.
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) make their picks for Week 6 in the SEC!Ole Miss at Vanderbilt (8:00), Missouri at Florida (16:00), Auburn at Georgia (22:00), South Carolina at Kentucky (27:00), Arkansas at Mississippi State (35:00), Texas A&M at Alabama (42:00), Tennessee at LSU (47:30)Please help support the show by taking advantage of our sponsor's offers:GameTime SIDEKICKS: 15% off officially licensed NCAA team gear with promo: heybuddy Link: www.gametimesidekicks.com WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) talkin' SEC football!LSU is opening gates and selling beer at 9 am! (1:00), discussing the toughest game on the schedule for the entire SEC (2:30), Sam Pittman with a KJ Jefferson update (41:00), Auburn at Georgia preview (42:15), Missouri at Florida preview (57:00), Ole Miss at Vanderbilt — Trap game? (1:03:00)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) preview the upcoming slate of SEC games!Does Alabama need Jalen Milroe to beat Texas A&M? (2:00), Jimbo Fisher stuck in his ways or will he adapt his offense? (15:30), can LSU put together a complete game to knock off Tennessee? (18:15), how difficult will it be for Tennessee to turn the page and win on the road at LSU? (28:45), can Kentucky easily bounce back from first loss of the season? (37:00), can the Gamecocks pull off another upset under Shane Beamer? Beamer tells a great recruiting story (45:45), Mississippi State and Arkansas preview (54:30)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) is joined by Steven Lassan (@AthlonSteven) to preview the upcoming week of SEC games!Mike back on “The Paul Finebaum Show” to roast Jimbo Fisher (1:30), Nick Saban comments on Bryce Young's status (9:00), Jimbo Fisher on Texas A&M's QB situation following Max Johnson's injury (11:30), Sam Pittman on KJ Jefferson's status after suffering an injury against Alabama (13:30), Brian Kelly says Jayden Daniels is good to go (14:30), Josh Heupel on Cedric Tillman's status (16:00), Steven Lassan of Athlon Sports joins the show to preview all seven SEC matchups this weekend! (17:00)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) recap the Week 5 SEC action!Ole Miss beats Kentucky, improves to 5-0 thanks in large part to the Rebel defense (3:00), Georgia holds on for a comeback win on the road at Missouri (16:00), Alabama earns a big win at Arkansas but Bryce Young is injured in the game (29:00), Texas A&M in turmoil as Mississippi State dominates every phase of the game in big win (45:30), Auburn blows yet another double-digit SEC lead (57:30)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) make their Week 5 SEC predictions!South Carolina wins but it wasn't as impressive as the final score would indicate (2:00), #1 Georgia at Missouri (12:30), LSU at Auburn (19:45), #17 Texas A&M at Mississippi State (25:00), #2 Alabama at #20 Arkansas (32:30), #7 Kentucky at #14 Ole Miss (43:45)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io All show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) is joined by Neal McCready (@NealMcCready) and Adam Luckett (@AdamLuckettKSR) to preview the Kentucky at Ole Miss game!Kyle Pitts in Checkerboard overalls (1:00), Neal McCready of Rebel Grove joins the show (2:30), Adam Luckett of Kentucky Sports Radio joins the show (30:15), Georgia's dominance calculated; Kirby Smart preview Missouri (46:30), Mizzou facing some adversity heading into Georgia week; Eli Drinkwitz on trusting the process and having Harrison Mevis' back (55:30), LSU taking shape under Brian Kelly? (1:04:30), Bryan Harsin says Auburn will continue to utilize two-QB system heading into LSU game (1:09:00)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io All show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) is joined by Chris Marler (@VerneFUNquist) to discuss the upcoming slate of SEC games!South Carolina vs South Carolina State moved to Thursday night (3:00), Florida vs Eastern Washington (4:30), Chris Marler of Saturday Down South and College Football Uncensored Podcast joins the show! (5:00), Kentucky at Ole Miss preview featuring Mark Stoops and Lane Kiffin comments (26:16), Alabama at Arkansas preview featuring Nick Saban and Sam Pittman comments (40:45), Texas A&M at Mississippi State preview with Jimbo Fisher and Mike Leach comments (53:30)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastWe have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) is joined by Steven Lassan (@AthlonSteven) to discuss the upcoming slate of SEC games!SEC reveals Oct. 8 kickoff and broadcast schedule (1:30), Steven Lassan stops by for his weekly segment! (6:00), Steven shares his thoughts on last weekend's results in the SEC (7:00), Steven power ranks the SEC's undefeated teams (15:00), which 1-loss SEC teams could have the best season? (19:20), Texas A&M at Mississippi State preview (28:30), Kentucky at Ole Miss preview (37:45), Alabama at Arkansas preview (44:00), Georgia at Missouri preview (52:15)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastShow call-in number: 615-800-5683We have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
SEC Mike Bratton (@MichaelWBratton) and his Cousin Shane (@BigOrangeVolz) recap the Week 4 SEC action!Tennessee snaps Florida losing streak and nearly cause Vol Nation to have heart attack in the process (2:00), Texas A&M fights back to beat Arkansas in wild ending in Arlington (19:30), Auburn and Missouri play one of the ugliest games in SEC history (37:00), Alabama destroy Vanderbilt with best all-around performance of the season (46:30), even Georgia is capable of looking ahead this season (49:30), Kentucky puts NIU away late to stay unbeaten (56:30), Ole Miss plays a good half of football but that was enough to beat Tulsa (1:03:00), South Carolina rebounds with great offense; forcing turnovers (1:09:00), LSU plays first complete game; dominates New Mexico (1:11:30)Please help support the show by taking advantage of our sponsor's offers:WAGR - Sports Betting App (All new users get FREE $20 to wager with promo code: SEC — Link: https://wagr.me/SECPRIZE PICKS - Daily Fantasy Sports (Matching initial deposit up to $100 with promo code: SEC — Link https://app.prizepicks.com/sign-up?invite_code=SECGUARDIAN BRACE: for a free 30-day trial or to learn more about Rehabilitator technology and Clinical Studies, visit www.freebody.io FUBO TV -- Try FUBO TV for FREE for 7 days, AND get 15% off your first month -- Link: https://fubotv.com/SECAll show music comes via Nashville band Crimson Calamity; check out their work by clicking the link below: https://open.spotify.com/artist/29HGeJEcYHBJlyt4xIcLBw?si=GJoEOr0YSoeqWkrjhCc0UgAdvertising inquiries: thatsecpodcast@gmail.comDonate to cousin Shane's beer fund via CashApp: $thatSECpodcastShow call-in number: 615-800-5683We have t-shirts for sale! Check out our merchandise store featuring shirts, hoodies, stickers, coffee mugs, pillows, phone cases and more:https://www.teepublic.com/stores/thatsecpodcast?ref_id=19055
© 2020-2025 Ivy Podcast Discovery LLC
